Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu, R. H. Shaw, Arabella Stuart, Melanie Greenland, Parvinder K. Aley, Nick Andrews, J. Claire Cameron, Sue Charlton, Elizabeth Clutterbuck, Andrea M. Collins, Tanya Dinesh, Anna England, Saul N. Faust, Daniela M. Ferreira, Adam Finn, Christopher Green, Bassam Hallis, Paul T. Heath, Helen Hill, Teresa Lambe, Rajeka Lazarus, Vincenzo Libri, Fei Long, Yama F Mujadidi, Emma L Plested, Samuel Provstgaard-Morys, Maheshi Ramasamy, Mary Ramsay, Robert C. Read, Hannah Robinson, Nisha Singh, David P. J. Turner, Paul Turner, L L Walker, Rachel White, Jonathan S Nguyen-Van-Tam, Matthew D. Snape, Alasdair Munro, Jazz Bartholomew, Laura Presland, Sarah Horswill, Sarah Warren, Sophie Varkonyi-Clifford, Stephen Saich, Kirsty Adams, Marivic Ricamara, Nicola Turner, Nicole Y Yee Ting, Sarah Whittley, Tommy Rampling, Amisha Desai, Claire Brown, Ehsaan Qureshi, Karishma Gokani, Kush Naker, Johanna Kellett Wright, Rachel Williams, Tawassal Riaz, Florentina Penciu, Claudio Di Maso, Elizabeth Howe, Iason Vichos, Mujtaba Ghulam Farooq, Rabiullah Noristani, Xin L Yao, Neil J. Oldfield, Daniel Hammersley, Sue Belton, Simon Royal, Alberto San Francisco Ramos, Cecilia Hultin, Eva Galiza, Farah Shiham, Carla Solórzano, Hannah Sainsbury, Kelly Davies, Pauline Ambrose, Lisa Hitchins, Natalie Baker, Stephanie Leung, Ross Fothergill, Kerry Godwin, Karen R. Buttigieg, Imam H. Shaik, Phill Brown, Chanice Knight, Paminder Lall, Lauren Allen